TY - JOUR
T1 - Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity
AU - Wang, Jing
AU - Ni, Shuangshuang
AU - Chen, Qian Qian
AU - Wang, Chenchen
AU - Liu, Hao
AU - Huang, Lina
AU - Nasir, Muhammad Waqas
AU - Wang, Wei
AU - Zhang, Xiangyu
AU - Wu, Jianjun
AU - Liu, Zhirong
AU - Wu, Jiabing
AU - Zhang, Liangmin
AU - Gao, Yong
N1 - Publisher Copyright:
© 2024 Wiley Periodicals LLC.
PY - 2024/12
Y1 - 2024/12
N2 - While the SARS-CoV-2 vaccine offers 70%–95% protection effectiveness against Coronavirus disease 2019 (COVID-19), a portion of recipients do not produce adequate protective immune responses, particularly, neutralizing antibodies (nAbs). Previous studies of COVID-19 patients have identified several public antibody lineages, such as IGHV3-30, IGHV3-33, IGHV3-53, IGHV1-58, and IGHV1-24. However, it remains unclear how these public antibodies evolve during vaccination or whether there are any special antibody lineages correlated with SARS-CoV-2 vaccination. In this study, through a combination of single B cell sequencing and next-generation sequencing analysis, we systemically studied the dynamic changes of antibody lineages derived from different B cell germlines in their sequence, frequency, and neutralization ability in different vaccinees before and after receiving inactivated SARS-CoV-2 vaccines. Our findings indicate that the frequency of antibodies derived from the IGHV4-34 lineage increased in most individuals after vaccination, and the higher frequency of the antibody usually resulted in stronger binding affinity. Additionally, the ratio of IGHV4-34 derived antibodies, when compared with other public antibodies, more strongly correlated with the neutralization activity of immune sera from vaccinees. Taken together, these results suggest that IGHV4-34 is a novel vaccine-elicited public nAb lineage that plays a crucial role in immune response following inactivated COVID-19 vaccination.
AB - While the SARS-CoV-2 vaccine offers 70%–95% protection effectiveness against Coronavirus disease 2019 (COVID-19), a portion of recipients do not produce adequate protective immune responses, particularly, neutralizing antibodies (nAbs). Previous studies of COVID-19 patients have identified several public antibody lineages, such as IGHV3-30, IGHV3-33, IGHV3-53, IGHV1-58, and IGHV1-24. However, it remains unclear how these public antibodies evolve during vaccination or whether there are any special antibody lineages correlated with SARS-CoV-2 vaccination. In this study, through a combination of single B cell sequencing and next-generation sequencing analysis, we systemically studied the dynamic changes of antibody lineages derived from different B cell germlines in their sequence, frequency, and neutralization ability in different vaccinees before and after receiving inactivated SARS-CoV-2 vaccines. Our findings indicate that the frequency of antibodies derived from the IGHV4-34 lineage increased in most individuals after vaccination, and the higher frequency of the antibody usually resulted in stronger binding affinity. Additionally, the ratio of IGHV4-34 derived antibodies, when compared with other public antibodies, more strongly correlated with the neutralization activity of immune sera from vaccinees. Taken together, these results suggest that IGHV4-34 is a novel vaccine-elicited public nAb lineage that plays a crucial role in immune response following inactivated COVID-19 vaccination.
UR - http://www.scopus.com/inward/record.url?scp=85210602559&partnerID=8YFLogxK
U2 - 10.1002/jmv.70073
DO - 10.1002/jmv.70073
M3 - Article
AN - SCOPUS:85210602559
SN - 0146-6615
VL - 96
JO - Journal of Medical Virology
JF - Journal of Medical Virology
IS - 12
M1 - e70073
ER -